Cellular aggregates for use in vascularisation therapy
AssigneeUniversidad Del Pais Vasco/Euskal Herriko Unibertsitatea
InventorsJOSÉ RAMÓN PINEDA MARTÍ, JON LUZURIAGA GONZÁLEZ, FERNANDO UNDA RODRÍGUEZ, OIER PASTOR ALONSO, JUAN MANUEL ENCINAS PÉREZ, GASKON IBARRETXE BILBAO, IGOR IRASTORZA EPELDE
Life of this patent
Estimating the term…
Abstract
A serum-free endothelial cell differentiation culture medium including (a) a basal culture medium and (b) an endothelial cell differentiation combination of EGF, FGF and VEGF protein. In the culture medium, the amount of EGF is higher than the amount of FGF protein. A process for the preparation of cellular aggregate suspensions comprising differentiated endothelial cells from dental stem cells using the serum-free medium. The use of the resulting suspension in therapy.
Claims11
-21. (canceled)
A method for the treatment of a disease caused by a reduction in the amount of laminin, or for promoting a process selected from the list consisting of tissue regeneration, angiogenesis, vasculogenesis, neuroprotection, and any combination thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of:
- A) a cellular aggregate comprising dental stem cells and differentiated endothelial cells, wherein the cellular aggregate is obtainable by an in-vitro serum-free process, the process comprising culturing in suspension an isolated sample comprising dental stem cells in a serum-free cell culture medium which is selected from:
- (a) a serum-free culture medium comprising a basal culture medium, and an endothelial cell differentiation combination of EGF and a FGF protein, wherein the amount of EGF is higher than the amount of FGF protein;
- (b) a serum-free culture medium comprising a basal culture medium, EGF, FGF, heparin and a cell supplement, wherein the amount of EGF is higher than the amount of FGF protein;
- and
- (c) a serum-free culture medium comprising:
- (i) a serum-free basal culture medium and
- (ii) an endothelial cell differentiation combination of VEGF, EGF and a FGF protein, wherein the amount of EGF is higher than the amount of FGF protein, or
- B) a culture comprising the cellular aggregate of A);
- or
- C) a pharmaceutical composition comprising the cellular aggregate of A), and pharmaceutically acceptable excipients or carriers.
Dependencies are inferred from the claim text.